لينكوميسين

Also known as Frademicina, Lincocin, Cillimycin, U-10149, Lincomycine, LCM, Methyl 6,8-dideoxy-6-trans-(1-methyl-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-D-erythro-alpha-D-galacto-octopyranoside, Lincomycin

مركب كيميائي

In the Vinony graph

Within Vinony's link graph, لينكوميسين is referenced by 146 other articles, and connects out to neomycin, macrolides and lincosamides.

It sits within the topics Drugboxes which contain changes to verified fields, Drugboxes which contain changes to watched fields and Drugs developed by Pfizer.

Its subject is documented across 28 Wikipedia language editions.

Key facts

Drug.Verifiedfields: changed
Drug.Watchedfields: changed
Drug.verifiedrevid: 408578167
Drug.IUPAC_name: (2S,4R)-N-[(1R,2R)-2-Hydroxy-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(methylsulfanyl)oxan-2-yl]propyl]-1-methyl-4-propylpyrrolidine-2-carboxamide
Drug.image: Lincomycin.svg
Drug.image_class: skin-invert-image
Drug.image2: Lincomycin molecule ball.png
Drug.image_class2: bg-transparent
Drug.width2: 250
Drug.alt2: Ball-and-stick model of lincomycin
Drug.tradename: Biocine, Lincocin
Drug.MedlinePlus: a609005
Drug.routes_of_administration: IM/IV
Drug.ATC_prefix: J01
Drug.ATC_suffix: FF02
Drug.legal_AU: S4
Drug.legal_US: Rx-only
Drug.bioavailability: N/A

via Wikipedia infobox

Chemical data

Formula: C18H34N2O6S
Molecular weight: 406.5 g/mol
IUPAC name: (2S,4R)-N-[(1R,2R)-2-hydroxy-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl]propyl]-1-methyl-4-propylpyrrolidine-2-carboxamide
SMILES: CCC[C@@H]1C[C@H](N(C1)C)C(=O)N[C@@H]([C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)SC)O)O)O)[C@@H](C)O
InChIKey: OJMMVQQUTAEWLP-KIDUDLJLSA-N
XLogP: 0.2
Polar surface area: 148 Å²
H-bond donors: 5
H-bond acceptors: 8
Formal charge: 0

via PubChem

Drug data · ChEMBL

Max clinical phase: Approved
Molecule type: Small molecule
First approval: 1964
Admin. routes: oral, parenteral
Indications: osteomyelitis, bacterial disease, multiple sclerosis

via ChEMBL · EBI

Research

10,119 papers

Lincomycin.Pediatric clinics of North America · 1968
Lincomycin and clindamycin.Antibiotics and chemotherapy · 1978
Lincomycin, clindamycin and their applications.Applied microbiology and biotechnology · 2004
[Antibiotic lincomycin].Antibiotiki · 1968
Lincomycin: fact, fancy, and future.The Medical clinics of North America · 1970

via PubMed

Wikidata facts

Has part: carbon
Mass: 406.214
Has use: medication

Show 8 more facts

Commons category: Lincomycin
chemical formula: C₁₈H₃₄N₂O₆S
canonical SMILES: CCCC1CC(N(C1)C)C(=O)NC(C2C(C(C(C(O2)SC)O)O)O)C(C)O
isomeric SMILES: CCC[C@@H]1C[C@H](N(C1)C)C(=O)N[C@@H]([C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)SC)O)O)O)[C@@H](C)O
World Health Organisation international non-proprietary name: lincomycin
medical condition treated: pneumococcal infection
subject has role: protein synthesis inhibitor
legal status (medicine): boxed warning

Sources (7)

via Wikidata · CC0

Article · العربية

لينكوميسين (بالإنجليزية: Lincomycin)‏ هو مضاد حيوي من عائلة اللينكوساميدات يأتي من شعيات المتسلسلة اللينكونية. والكلينداميسين هو مضاد حيوي مشتق من اللينكوميسين تم اشتقاقه عن طريق استخدام كلوريد الثيونيل (SOCl2)، وذلك باستبدال مجموعة الـ7-هيدروكسل بذرة كلور وعكس اللانطباقية المرآتية للذرات (ترتيب الذرات). وتم إصدار اللينكوميسين للاستخدام الطبي في سبتمبر 1964.

Abstract from DBpedia / Wikipedia · CC BY-SA